A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer

被引:11
作者
Miller, Jessica J. [1 ]
Kwan, Kalvin [1 ]
Gaiddon, Christian [2 ]
Storr, Tim [1 ]
机构
[1] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada
[2] Strasbourg Univ, IRFAC, Team Streinth, Inserm UMR S1113, Strasbourg, France
来源
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY | 2022年 / 27卷 / 4-5期
基金
加拿大自然科学与工程研究理事会;
关键词
Anticancer agents; Mutant protein reactivation; Metallochaperones; DNA-BINDING DOMAIN; SMALL-MOLECULE; ZINC METALLOCHAPERONES; WILD-TYPE; POSTTRANSLATIONAL MODIFICATION; AMYLOID STATE; CELL-DEATH; TP53; GENE; AGGREGATION; PATHWAY;
D O I
10.1007/s00775-022-01939-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metal ion dysregulation has been implicated in a number of diseases from neurodegeneration to cancer. While defective metal ion transport mechanisms are known to cause specific diseases of genetic origin, the role of metal dysregulation in many diseases has yet to be elucidated due to the complicated function (both good and bad!) of metal ions in the body. A breakdown in metal ion speciation can manifest in several ways from increased reactive oxygen species (ROS) generation to an increase in protein misfolding and aggregation. In this review, we will discuss the role of Zn in the proper function of the p53 protein in cancer. The p53 protein plays a critical role in the prevention of genome mutations via initiation of apoptosis, DNA repair, cell cycle arrest, anti-angiogenesis, and senescence pathways to avoid propagation of damaged cells. p53 is the most frequently mutated protein in cancer and almost all cancers exhibit malfunction along the p53 pathway. Thus, there has been considerable effort dedicated to restoring normal p53 expression and activity to mutant p53. This includes understanding the relative populations of the Zn-bound and Zn-free p53 in wild-type and mutant forms, and the development of metallochaperones to re-populate the Zn binding site to restore mutant p53 activity. Parallels will be made to the development of multifunctional metal binding agents for modulating the aggregation of the amyloid-beta peptide in Alzheimer's Disease (AD). [GRAPHICS] .
引用
收藏
页码:393 / 403
页数:11
相关论文
共 140 条
  • [81] Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer
    Miller, Jessica J.
    Orvain, Christophe
    Jozi, Shireen
    Clarke, Ryan M.
    Smith, Jason R.
    Blanchet, Anais
    Gaiddon, Christian
    Warren, Jeffrey J.
    Storr, Tim
    [J]. CHEMISTRY-A EUROPEAN JOURNAL, 2018, 24 (67) : 17734 - 17742
  • [82] The MDM2 gene amplification database
    Momand, J
    Jung, D
    Wilczynski, S
    Niland, J
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (15) : 3453 - 3459
  • [83] Designed multiple ligands. An emerging drug discovery paradigm
    Morphy, R
    Rankovic, Z
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (21) : 6523 - 6543
  • [84] The MDM2-p53 pathway revisited
    Nag, Subhasree
    Qin, Jiangjiang
    Srivenugopal, Kalkunte S.
    Wang, Minghai
    Zhang, Ruiwen
    [J]. JOURNAL OF BIOMEDICAL RESEARCH, 2013, 27 (04): : 254 - 271
  • [85] Multiple reactivities of flavonoids towards pathological elements in Alzheimer's disease: structure-activity relationship
    Nam, Geewoo
    Hong, Mannkyu
    Lee, Juri
    Lee, Hyuck Jin
    Ji, Yonghwan
    Kang, Juhye
    Baik, Mu-Hyun
    Lim, Mi Hee
    [J]. CHEMICAL SCIENCE, 2020, 11 (37) : 10243 - 10254
  • [86] Interaction of the p53 DNA-Binding Domain with Its N-Terminal Extension Modulates the Stability of the p53 Tetramer
    Natan, Eviatar
    Baloglu, Cetin
    Pagel, Kevin
    Freund, Stefan M. V.
    Morgner, Nina
    Robinson, Carol V.
    Fersht, Alan R.
    Joerger, Andreas C.
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2011, 409 (03) : 358 - 368
  • [87] Prion-like p53 Amyloids in Cancer
    Navalkar, Ambuja
    Ghosh, Saikat
    Pandey, Satyaprakash
    Paul, Ajoy
    Datta, Debalina
    Maji, Samir K.
    [J]. BIOCHEMISTRY, 2020, 59 (02) : 146 - 155
  • [88] Recent advances in p53 research: an interdisciplinary perspective
    Olivier, M.
    Petitjean, A.
    Marcel, V.
    Petre, A.
    Mounawar, M.
    Plymoth, A.
    de Fromentel, C. C.
    Hainaut, P.
    [J]. CANCER GENE THERAPY, 2009, 16 (01) : 1 - 12
  • [89] TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
    Olivier, Magali
    Hollstein, Monica
    Hainaut, Pierre
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (01): : a001008
  • [90] Effects of TP53 mutational status on gene expression patterns across 10 human cancer types
    Parikh, Neha
    Hilsenbeck, Susan
    Creighton, Chad J.
    Dayaram, Tajhal
    Shuck, Ryan
    Shinbrot, Eve
    Xi, Liu
    Gibbs, Richard A.
    Wheeler, David A.
    Donehower, Lawrence A.
    [J]. JOURNAL OF PATHOLOGY, 2014, 232 (05) : 522 - 533